Options mapped

Anal cancer: options by country

Sourced options by country plus visit-prep questions for Anal cancer. Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedSolid tumorLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

Is the diagnosis anal canal squamous cell carcinoma, perianal skin cancer, or another anal tumor subtype?
Is treatment being planned for localized disease, residual/recurrent disease, or metastatic/inoperable locally recurrent disease?
Is retifanlimab being considered first-line with chemotherapy or after platinum progression/intolerance?
Has the EMA recommendation been converted into local authorization and reimbursement in the treating country?

Trial-search terms to discuss

Anal cancer clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

European Union

Retifanlimab (Zynyz) with carboplatin and paclitaxel [1]EMA authorisedNo biomarker requirement stated in fetched EMA news source; Adults with SCAC that cannot be removed by surgery and is metastatic or locally recurrent, in combination with carboplatin and paclitaxel. · The fetched EMA source is a recommendation/news page, not final EPAR product information; European Commission authorization status and member-state reimbursement must be verified separately. No claim is made for monotherapy EU use from this source. Confidence/conflicts: Medium-high for EMA CHMP recommendation; final authorization and country access remain follow-up gaps.
Retifanlimab (Zynyz) with carboplatin and paclitaxel [1]EMA authorisedNo biomarker requirement stated in fetched EMA news source; Adults with SCAC that cannot be removed by surgery and is metastatic or locally recurrent, in combination with carboplatin and paclitaxel. · The fetched EMA source is a recommendation/news page, not final EPAR product information; European Commission authorization status and member-state reimbursement must be verified separately. No claim is made for monotherapy EU use from this source. Confidence/conflicts: Medium-high for EMA CHMP recommendation; final authorization and country access remain follow-up gaps.
Retifanlimab (Zynyz) with carboplatin and paclitaxel [1]EMA authorisedNo biomarker requirement stated in fetched EMA news source; Adults with SCAC that cannot be removed by surgery and is metastatic or locally recurrent, in combination with carboplatin and paclitaxel. · The fetched EMA source is a recommendation/news page, not final EPAR product information; European Commission authorization status and member-state reimbursement must be verified separately. No claim is made for monotherapy EU use from this source. Confidence/conflicts: Medium-high for EMA CHMP recommendation; final authorization and country access remain follow-up gaps.

Sources

European Medicines Agency (EMA) — regulator recommendation news · regulator recommendation news

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

Chemoradiation with fluorouracil and mitomycin; radiation therapy; surgery for residual/recurrent disease; palliative surgery/radiation/chemoradiation; retifanlimab-dlwr (Zynyz) with carboplatin and paclitaxel; retifanlimab single agentClinical trialClinical trialReported in a clinical trialUnited States · No biomarker requirement stated in fetched NCI/FDA sources; HPV association is disease biology context, not a treatment-selection claim here; Localized anal cancer chemoradiation; residual/recurrent anal canal cancer after nonoperative therapy; stage IV palliative contexts; first-line inoperable locally recurrent or metastatic SCAC; post-platinum locally recurrent or metastatic SCAC. · NCI PDQ is an evidence summary, not payer guidance. FDA approval notice does not determine individual eligibility, toxicity suitability, or reimbursement. Retifanlimab indication is for squamous cell carcinoma of the anal canal as stated by FDA. Confidence/conflicts: High for U.S. framework and retifanlimab approval; payer/implementation details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
Chemoradiation with fluorouracil and mitomycin; radiation therapy; surgery for residual/recurrent disease; palliative surgery/radiation/chemoradiation; retifanlimab-dlwr (Zynyz) with carboplatin and paclitaxel; retifanlimab single agentClinical trialClinical trialReported in a clinical trialUnited States · No biomarker requirement stated in fetched NCI/FDA sources; HPV association is disease biology context, not a treatment-selection claim here; Localized anal cancer chemoradiation; residual/recurrent anal canal cancer after nonoperative therapy; stage IV palliative contexts; first-line inoperable locally recurrent or metastatic SCAC; post-platinum locally recurrent or metastatic SCAC. · NCI PDQ is an evidence summary, not payer guidance. FDA approval notice does not determine individual eligibility, toxicity suitability, or reimbursement. Retifanlimab indication is for squamous cell carcinoma of the anal canal as stated by FDA. Confidence/conflicts: High for U.S. framework and retifanlimab approval; payer/implementation details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
Chemoradiation with fluorouracil and mitomycin; radiation therapy; surgery for residual/recurrent disease; palliative surgery/radiation/chemoradiation; retifanlimab-dlwr (Zynyz) with carboplatin and paclitaxel; retifanlimab single agentClinical trialClinical trialReported in a clinical trialUnited States · No biomarker requirement stated in fetched NCI/FDA sources; HPV association is disease biology context, not a treatment-selection claim here; Localized anal cancer chemoradiation; residual/recurrent anal canal cancer after nonoperative therapy; stage IV palliative contexts; first-line inoperable locally recurrent or metastatic SCAC; post-platinum locally recurrent or metastatic SCAC. · NCI PDQ is an evidence summary, not payer guidance. FDA approval notice does not determine individual eligibility, toxicity suitability, or reimbursement. Retifanlimab indication is for squamous cell carcinoma of the anal canal as stated by FDA. Confidence/conflicts: High for U.S. framework and retifanlimab approval; payer/implementation details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
Chemoradiation with fluorouracil and mitomycin; radiation therapy; surgery for residual/recurrent disease; palliative surgery/radiation/chemoradiation; retifanlimab-dlwr (Zynyz) with carboplatin and paclitaxel; retifanlimab single agentClinical trialClinical trialReported in a clinical trialUnited States · No biomarker requirement stated in fetched NCI/FDA sources; HPV association is disease biology context, not a treatment-selection claim here; Localized anal cancer chemoradiation; residual/recurrent anal canal cancer after nonoperative therapy; stage IV palliative contexts; first-line inoperable locally recurrent or metastatic SCAC; post-platinum locally recurrent or metastatic SCAC. · NCI PDQ is an evidence summary, not payer guidance. FDA approval notice does not determine individual eligibility, toxicity suitability, or reimbursement. Retifanlimab indication is for squamous cell carcinoma of the anal canal as stated by FDA. Confidence/conflicts: High for U.S. framework and retifanlimab approval; payer/implementation details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
Chemoradiation with fluorouracil and mitomycin; radiation therapy; surgery for residual/recurrent disease; palliative surgery/radiation/chemoradiation; retifanlimab-dlwr (Zynyz) with carboplatin and paclitaxel; retifanlimab single agentClinical trialClinical trialReported in a clinical trialUnited States · No biomarker requirement stated in fetched NCI/FDA sources; HPV association is disease biology context, not a treatment-selection claim here; Localized anal cancer chemoradiation; residual/recurrent anal canal cancer after nonoperative therapy; stage IV palliative contexts; first-line inoperable locally recurrent or metastatic SCAC; post-platinum locally recurrent or metastatic SCAC. · NCI PDQ is an evidence summary, not payer guidance. FDA approval notice does not determine individual eligibility, toxicity suitability, or reimbursement. Retifanlimab indication is for squamous cell carcinoma of the anal canal as stated by FDA. Confidence/conflicts: High for U.S. framework and retifanlimab approval; payer/implementation details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
Chemoradiation with fluorouracil and mitomycin; radiation therapy; surgery for residual/recurrent disease; palliative surgery/radiation/chemoradiation; retifanlimab-dlwr (Zynyz) with carboplatin and paclitaxel; retifanlimab single agentClinical trialClinical trialReported in a clinical trialUnited States · No biomarker requirement stated in fetched NCI/FDA sources; HPV association is disease biology context, not a treatment-selection claim here; Localized anal cancer chemoradiation; residual/recurrent anal canal cancer after nonoperative therapy; stage IV palliative contexts; first-line inoperable locally recurrent or metastatic SCAC; post-platinum locally recurrent or metastatic SCAC. · NCI PDQ is an evidence summary, not payer guidance. FDA approval notice does not determine individual eligibility, toxicity suitability, or reimbursement. Retifanlimab indication is for squamous cell carcinoma of the anal canal as stated by FDA. Confidence/conflicts: High for U.S. framework and retifanlimab approval; payer/implementation details remain unverified. U.S. Food and Drug Administration (FDA) — regulator approval notice
Chemoradiotherapy combinations including mitomycin with fluorouracil or capecitabine; carboplatin plus paclitaxel; FOLFCIS; docetaxel; immunotherapy options including nivolumab, pembrolizumab, or retifanlimab as second-line options in the draft-scope contextClinical trialClinical trialInvestigationalUnited Kingdom · No biomarker requirement stated in fetched NICE draft scope; Chemoradiotherapy for anal canal cancer; inoperable anal canal cancer systemic chemotherapy; second-line post-chemotherapy immunotherapy draft-scope context. · NICE draft scope is not final NICE guidance or an MHRA label. The statement is useful for UK pathway context only; final reimbursement and recommendation status need separate verification. Confidence/conflicts: Medium because source is draft scope, not final guidance; final NICE/MHRA status remains active gap. NICE — technology appraisal draft scope
Chemoradiotherapy combinations including mitomycin with fluorouracil or capecitabine; carboplatin plus paclitaxel; FOLFCIS; docetaxel; immunotherapy options including nivolumab, pembrolizumab, or retifanlimab as second-line options in the draft-scope contextClinical trialClinical trialInvestigationalUnited Kingdom · No biomarker requirement stated in fetched NICE draft scope; Chemoradiotherapy for anal canal cancer; inoperable anal canal cancer systemic chemotherapy; second-line post-chemotherapy immunotherapy draft-scope context. · NICE draft scope is not final NICE guidance or an MHRA label. The statement is useful for UK pathway context only; final reimbursement and recommendation status need separate verification. Confidence/conflicts: Medium because source is draft scope, not final guidance; final NICE/MHRA status remains active gap. NICE — technology appraisal draft scope
Chemoradiotherapy combinations including mitomycin with fluorouracil or capecitabine; carboplatin plus paclitaxel; FOLFCIS; docetaxel; immunotherapy options including nivolumab, pembrolizumab, or retifanlimab as second-line options in the draft-scope contextClinical trialClinical trialInvestigationalUnited Kingdom · No biomarker requirement stated in fetched NICE draft scope; Chemoradiotherapy for anal canal cancer; inoperable anal canal cancer systemic chemotherapy; second-line post-chemotherapy immunotherapy draft-scope context. · NICE draft scope is not final NICE guidance or an MHRA label. The statement is useful for UK pathway context only; final reimbursement and recommendation status need separate verification. Confidence/conflicts: Medium because source is draft scope, not final guidance; final NICE/MHRA status remains active gap. NICE — technology appraisal draft scope
Chemoradiotherapy combinations including mitomycin with fluorouracil or capecitabine; carboplatin plus paclitaxel; FOLFCIS; docetaxel; immunotherapy options including nivolumab, pembrolizumab, or retifanlimab as second-line options in the draft-scope contextClinical trialClinical trialInvestigationalUnited Kingdom · No biomarker requirement stated in fetched NICE draft scope; Chemoradiotherapy for anal canal cancer; inoperable anal canal cancer systemic chemotherapy; second-line post-chemotherapy immunotherapy draft-scope context. · NICE draft scope is not final NICE guidance or an MHRA label. The statement is useful for UK pathway context only; final reimbursement and recommendation status need separate verification. Confidence/conflicts: Medium because source is draft scope, not final guidance; final NICE/MHRA status remains active gap. NICE — technology appraisal draft scope
Retifanlimab plus carboplatin/paclitaxel; KFA115 plus pembrolizumabClinical trial · NCT04472429Clinical trialTrial only (registry)Japan · No biomarker requirement stated for POD1UM-303 SCAC record; broad KFA115 study may have cohort-specific criteria; Locally advanced or metastatic SCAC; selected advanced cancer cohort including anal cancer. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. POD1UM-303 is completed; KFA115 is a broad phase 1 cohort. Confidence/conflicts: High for Japan registry-listed anal cancer activity; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
Retifanlimab plus carboplatin/paclitaxel; KFA115 plus pembrolizumabClinical trial · NCT04472429Clinical trialTrial only (registry)Japan · No biomarker requirement stated for POD1UM-303 SCAC record; broad KFA115 study may have cohort-specific criteria; Locally advanced or metastatic SCAC; selected advanced cancer cohort including anal cancer. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. POD1UM-303 is completed; KFA115 is a broad phase 1 cohort. Confidence/conflicts: High for Japan registry-listed anal cancer activity; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
Retifanlimab plus carboplatin/paclitaxel; KFA115 plus pembrolizumabClinical trial · NCT04472429Clinical trialTrial only (registry)Japan · No biomarker requirement stated for POD1UM-303 SCAC record; broad KFA115 study may have cohort-specific criteria; Locally advanced or metastatic SCAC; selected advanced cancer cohort including anal cancer. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. POD1UM-303 is completed; KFA115 is a broad phase 1 cohort. Confidence/conflicts: High for Japan registry-listed anal cancer activity; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
Vobramitamab duocarmazine; KFA115 plus pembrolizumab; BI 754091 alone or with BI 836880Clinical trial · NCT05551117Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea records; Advanced anal cancer cohort; advanced anal canal squamous cell carcinoma. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Two selected Korea records are terminated or withdrawn, and broad cohort studies require confirmation of anal cancer-specific enrollment. Confidence/conflicts: Medium-high for Korea registry-listed activity; current access is limited/uncertain. ClinicalTrials.gov — clinical-trial registry
Vobramitamab duocarmazine; KFA115 plus pembrolizumab; BI 754091 alone or with BI 836880Clinical trial · NCT05551117Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea records; Advanced anal cancer cohort; advanced anal canal squamous cell carcinoma. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Two selected Korea records are terminated or withdrawn, and broad cohort studies require confirmation of anal cancer-specific enrollment. Confidence/conflicts: Medium-high for Korea registry-listed activity; current access is limited/uncertain. ClinicalTrials.gov — clinical-trial registry
Vobramitamab duocarmazine; KFA115 plus pembrolizumab; BI 754091 alone or with BI 836880Clinical trial · NCT05551117Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea records; Advanced anal cancer cohort; advanced anal canal squamous cell carcinoma. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Two selected Korea records are terminated or withdrawn, and broad cohort studies require confirmation of anal cancer-specific enrollment. Confidence/conflicts: Medium-high for Korea registry-listed activity; current access is limited/uncertain. ClinicalTrials.gov — clinical-trial registry
CRTE7A2-01 TCR-T cell therapy after fludarabine/cyclophosphamide and interleukin-2; PD-1 inhibitor plus concurrent chemoradiotherapy; toripalimab with chemotherapy followed by concurrent immunoradiotherapyClinical trial · NCT05122221Clinical trialTrial only (registry)China · HPV-16 positive status required for CRTE7A2-01 TCR-T study; HPV-16 positive advanced anal cancer; stage I-III anal canal/anal squamous cell carcinoma; locally advanced SCCA. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment, or individual eligibility. HPV-16 positivity and protocol-specific staging requirements must be confirmed. Confidence/conflicts: High for China registry-listed anal cancer study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
CRTE7A2-01 TCR-T cell therapy after fludarabine/cyclophosphamide and interleukin-2; PD-1 inhibitor plus concurrent chemoradiotherapy; toripalimab with chemotherapy followed by concurrent immunoradiotherapyClinical trial · NCT05122221Clinical trialTrial only (registry)China · HPV-16 positive status required for CRTE7A2-01 TCR-T study; HPV-16 positive advanced anal cancer; stage I-III anal canal/anal squamous cell carcinoma; locally advanced SCCA. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment, or individual eligibility. HPV-16 positivity and protocol-specific staging requirements must be confirmed. Confidence/conflicts: High for China registry-listed anal cancer study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
CRTE7A2-01 TCR-T cell therapy after fludarabine/cyclophosphamide and interleukin-2; PD-1 inhibitor plus concurrent chemoradiotherapy; toripalimab with chemotherapy followed by concurrent immunoradiotherapyClinical trial · NCT05122221Clinical trialTrial only (registry)China · HPV-16 positive status required for CRTE7A2-01 TCR-T study; HPV-16 positive advanced anal cancer; stage I-III anal canal/anal squamous cell carcinoma; locally advanced SCCA. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment, or individual eligibility. HPV-16 positivity and protocol-specific staging requirements must be confirmed. Confidence/conflicts: High for China registry-listed anal cancer study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
CRTE7A2-01 TCR-T cell therapy after fludarabine/cyclophosphamide and interleukin-2; PD-1 inhibitor plus concurrent chemoradiotherapy; toripalimab with chemotherapy followed by concurrent immunoradiotherapyClinical trial · NCT05122221Clinical trialTrial only (registry)China · HPV-16 positive status required for CRTE7A2-01 TCR-T study; HPV-16 positive advanced anal cancer; stage I-III anal canal/anal squamous cell carcinoma; locally advanced SCCA. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment, or individual eligibility. HPV-16 positivity and protocol-specific staging requirements must be confirmed. Confidence/conflicts: High for China registry-listed anal cancer study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
CRTE7A2-01 TCR-T cell therapy after fludarabine/cyclophosphamide and interleukin-2; PD-1 inhibitor plus concurrent chemoradiotherapy; toripalimab with chemotherapy followed by concurrent immunoradiotherapyClinical trial · NCT05122221Clinical trialTrial only (registry)China · HPV-16 positive status required for CRTE7A2-01 TCR-T study; HPV-16 positive advanced anal cancer; stage I-III anal canal/anal squamous cell carcinoma; locally advanced SCCA. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment, or individual eligibility. HPV-16 positivity and protocol-specific staging requirements must be confirmed. Confidence/conflicts: High for China registry-listed anal cancer study activity; NMPA/access unverified. ClinicalTrials.gov — clinical-trial registry
Stimotimagene copolymerplasmid plus ganciclovirClinical trial · NCT05578820Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia record; Broad tumor-type study including anus neoplasms. · Registry record does not establish Russian regulator approval, reimbursement, routine access, current availability, or anal cancer-specific enrollment at each site. Confidence/conflicts: Medium for Russia broad anus-neoplasm registry activity; anal cancer-specific access unverified. ClinicalTrials.gov — clinical-trial registry
Stimotimagene copolymerplasmid plus ganciclovirClinical trial · NCT05578820Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia record; Broad tumor-type study including anus neoplasms. · Registry record does not establish Russian regulator approval, reimbursement, routine access, current availability, or anal cancer-specific enrollment at each site. Confidence/conflicts: Medium for Russia broad anus-neoplasm registry activity; anal cancer-specific access unverified. ClinicalTrials.gov — clinical-trial registry
Stimotimagene copolymerplasmid plus ganciclovirClinical trial · NCT05578820Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia record; Broad tumor-type study including anus neoplasms. · Registry record does not establish Russian regulator approval, reimbursement, routine access, current availability, or anal cancer-specific enrollment at each site. Confidence/conflicts: Medium for Russia broad anus-neoplasm registry activity; anal cancer-specific access unverified. ClinicalTrials.gov — clinical-trial registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.